On the Frontlines of ATTR-CM
Welcome to On the Frontlines of ATTR-CM, a series that delivers timely, practice-relevant insights from leading experts who are shaping the field. So whether you’re sharpening your diagnostic skills or staying ahead of therapeutic advances, tune in to gain knowledge that can help transform patient outcomes.
1-15 of 22
Refining Nuclear Scintigraphy for ATTR-CM Diagnosis
On the Frontlines of ATTR-CMRefining Nuclear Scintigraphy for ATTR-CM Diagnosis
Mary Leuchars, MD
Saurabh Malhotra, MD, MPH, FASNC
Heart Transplant in ATTR-CM: A New Look at Referral and Candidacy
On the Frontlines of ATTR-CMHeart Transplant in ATTR-CM: A New Look at Referral and Candidacy
Steve Jackson, PharmD
Alex Reyentovich, MD
The Role of TTR Stabilization in ATTR-CM Treatment
On the Frontlines of ATTR-CMThe Role of TTR Stabilization in ATTR-CM Treatment
Steve Jackson, PharmD
Sumeet Mitter MD, MSc, FACC
Early Detection of ATTR-CM: Clinical Clues and Imaging Approaches
On the Frontlines of ATTR-CMEarly Detection of ATTR-CM: Clinical Clues and Imaging Approaches
Shelina Ramnarine, PhD
Valmiki Maharaj, MD
Recognizing and Managing Swelling in ATTR-CM
On the Frontlines of ATTR-CMRecognizing and Managing Swelling in ATTR-CM
Steve Jackson, PharmD
Kevin S. Shah, MD
Understanding Real-World Testing Patterns in ATTR-CM
On the Frontlines of ATTR-CMUnderstanding Real-World Testing Patterns in ATTR-CM
Steve Jackson, PharmD
Ronald Witteles, MD
- advertisement
Recognizing ATTR-CM in High-Risk Populations
On the Frontlines of ATTR-CMRecognizing ATTR-CM in High-Risk Populations
Steve Jackson, PharmD
Frederick Ruberg, MD
Aligning ATTR-CM Care With Patient Preferences
On the Frontlines of ATTR-CMAligning ATTR-CM Care With Patient Preferences
Steve Jackson, PharmD
Joshua D. Mitchell, MD, MSCI, FACC
Redefining ATTR-CM Care in the Age of Targeted Therapy
On the Frontlines of ATTR-CMRedefining ATTR-CM Care in the Age of Targeted Therapy
Steve Jackson, PharmD
David Rind, MD, MSc
Tracking Disease Progression in ATTR-CM
On the Frontlines of ATTR-CMTracking Disease Progression in ATTR-CM
Ryan Quigley
Joban Vaishnav, MD
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
On the Frontlines of ATTR-CMUnderstanding Vutrisiran’s Cardiac Effects in HELIOS-B
Steve Jackson, PharmD
Karola Jering, MD
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CMRNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
Shelina Ramnarine, PhD
Chadi Alraies, MD, MPH, FACC
- advertisement
Can AI Transform How We Diagnose ATTR-CM?
On the Frontlines of ATTR-CMCan AI Transform How We Diagnose ATTR-CM?
Ryan Quigley
Frederick Ruberg, MD
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
On the Frontlines of ATTR-CMATTRibute-CM Findings on Acoramidis and Cumulative CV Events
Ryan Quigley
Ahmad Masri, MD, MS
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
On the Frontlines of ATTR-CMATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
Ryan Quigley
Kevin Alexander, MD